Jeffrey Borgia to Middle Aged
This is a "connection" page, showing publications Jeffrey Borgia has written about Middle Aged.
Connection Strength
0.826
-
Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy. J Cachexia Sarcopenia Muscle. 2024 Dec; 15(6):2311-2322.
Score: 0.095
-
Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions. Hum Immunol. 2018 Jul; 79(7):558-563.
Score: 0.061
-
The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
Score: 0.061
-
Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
Score: 0.059
-
Impact of cachexia on outcomes in aggressive lymphomas. Ann Hematol. 2017 Jun; 96(6):951-956.
Score: 0.057
-
Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. Ann Thorac Surg. 2015 Aug; 100(2):429-36.
Score: 0.050
-
Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
Score: 0.048
-
Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
Score: 0.048
-
Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013 Jan; 8(1):31-6.
Score: 0.042
-
Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
Score: 0.042
-
Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
Score: 0.039
-
Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
Score: 0.037
-
A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
Score: 0.036
-
Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
Score: 0.033
-
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer. Mol Cancer. 2024 Nov 06; 23(1):247.
Score: 0.024
-
The MindMoves Trial: Cross-Sectional Analyses of Baseline Vascular Risk and Cognition in Older Women with Cardiovascular Disease. J Alzheimers Dis. 2024; 100(4):1407-1416.
Score: 0.023
-
A pan-cancer organoid platform for precision medicine. Cell Rep. 2021 07 27; 36(4):109429.
Score: 0.019
-
Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening. BMC Genomics. 2018 Jul 20; 19(1):545.
Score: 0.016
-
Anti-vimentin Antibodies Present at the Time of Transplantation May Predict Early Development of Interstitial Fibrosis/Tubular Atrophy. Transplant Proc. 2016 Jul-Aug; 48(6):2023-33.
Score: 0.014
-
Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42.
Score: 0.012
-
Incomplete elongation of the chondroitin sulfate linkage region on aggrecan and response to interleukin-1?. Connect Tissue Res. 2013; 54(2):123-31.
Score: 0.011